Back HIV Policy & Advocacy

HIV Policy & Advocacy

Medicines Patent Pool Licenses First HIV and HBV Drugs

UNITAID and the Medicines Patent Pool -- an initiative to make drugs more widely available at reduced cost -- announced its first pharmaceutical company agreement. Gilead Sciences licensed 4 drugs, including the popular tenofovir for treatment of HIV and hepatitis B, as well as coformulation including Truvada and the experimental Quad pill.alt

Read more:

IAS 2011: Universal Access to Science [VIDEO]

Michel Sidibé, Executive Director of UNAIDS, spoke Sunday, July 7, at the opening plenary and press conference of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011).alt

Read more:

U.N. Report Looks at Global HIV/AIDS Response

New U.N. report finds that HIV infection have fallen by more than 25% in over 30 countries and more than 6 million people worldwide are on antiretroviral treatment, but much remains to be done.

Read more:

IAS 2011: Biomedical Prevention a Watershed, Global Access Remains Elusive

The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) opened Sunday with applause for recent breakthroughs in biomedical prevention of HIV transmission, coupled with acknowledgement that much remains to be done to bring the benefits of science to people with and at risk for HIV/AIDS worldwide. alt

Read more:

Institute of Medicine Outlines HIV Care Capacity

More HIV services will be needed for people identified as HIV positive through stepped-up screening, according to the Institute of Medicine.

Read more: